Greenwich LifeSciences (NASDAQ:GLSI) Stock Price Down 0.2% - What's Next?

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report)'s stock price traded down 0.2% on Friday . The stock traded as low as $8.90 and last traded at $8.90. 33,040 shares changed hands during trading, a decline of 28% from the average session volume of 46,134 shares. The stock had previously closed at $8.92.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright raised their target price on shares of Greenwich LifeSciences from $38.00 to $39.00 and gave the company a "buy" rating in a research note on Monday, April 21st.

Greenwich LifeSciences Price Performance

The business's 50 day simple moving average is $9.58 and its 200-day simple moving average is $11.05. The stock has a market capitalization of $120.98 million, a P/E ratio of -7.18 and a beta of 1.69.

Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) last posted its quarterly earnings results on Tuesday, May 20th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.01). Research analysts anticipate that Greenwich LifeSciences, Inc. will post -0.8 earnings per share for the current fiscal year.

Insider Transactions at Greenwich LifeSciences

In other news, CEO Snehal Patel purchased 3,600 shares of the firm's stock in a transaction dated Friday, April 25th. The stock was bought at an average price of $9.88 per share, with a total value of $35,568.00. Following the acquisition, the chief executive officer now directly owns 5,570,602 shares of the company's stock, valued at approximately $55,037,547.76. This represents a 0.06% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last ninety days, insiders purchased 18,100 shares of company stock worth $164,835. 51.67% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC bought a new stake in shares of Greenwich LifeSciences in the first quarter worth about $126,000. Wells Fargo & Company MN grew its position in shares of Greenwich LifeSciences by 54.8% in the 4th quarter. Wells Fargo & Company MN now owns 2,847 shares of the company's stock valued at $32,000 after purchasing an additional 1,008 shares during the period. Brown Brothers Harriman & Co. bought a new stake in Greenwich LifeSciences during the 4th quarter worth approximately $45,000. JPMorgan Chase & Co. raised its holdings in Greenwich LifeSciences by 172.0% during the 4th quarter. JPMorgan Chase & Co. now owns 7,061 shares of the company's stock worth $79,000 after buying an additional 4,465 shares during the period. Finally, Bank of America Corp DE lifted its stake in Greenwich LifeSciences by 22.3% in the fourth quarter. Bank of America Corp DE now owns 7,262 shares of the company's stock valued at $82,000 after buying an additional 1,322 shares in the last quarter. 4.16% of the stock is currently owned by institutional investors.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.